Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management.

摘要: Fenofibrate is among the drugs of choice for treatment hypertriglyceridaemia and low levels high-density lipoprotein (HDL)-cholesterol, both recognised as risk factors cardiovascular disease. Recently, a number studies have shown an elevation homocysteine with fenofibrate or bezafibrate therapy. Homocysteine atherogenic amino acid derived from methionine cycle. At present, underlying mechanism this has not been elucidated. While deterioration vitamin status does seem to be involved, impairment renal function changes in creatine metabolism are regarded probable mechanisms. In patients receiving lipid-lowering drugs, supplementation folic B12 effectively reduces plasma level. Two that addition combination prevented most increase associated fenofibrate. Although consequence increasing proven at it considered will given long-term treatment. Therefore, can recommended prevent fenofibrate, could changed gemfibrozil, which levels.